XML 48 R36.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting

Schedule of information about the Company's single segment


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2025			2024			2025			2024
Revenue		$	14,544		$	15,425		$	38,701		$	46,641
Cost of product revenue			1,774			1,561			4,980			4,396
Research and development (a)
Direct program expenses
AXPAXLI for wet AMD			34,707			17,017			92,893			35,263
Other clinical and preclinical programs			1,224			1,184			3,307			6,750
Unallocated expenses
Personnel costs			9,136			7,551			27,825			22,168
All other costs			1,632			6,365			5,986			8,815
Selling and marketing (a)			11,721			9,601			36,972			27,997
General and administrative (a)			8,563			8,832			26,864			28,294
Facilities (b)			1,722			1,713			5,230			5,416
Stock-based compensation			11,691			6,641			31,825			25,912
Depreciation			1,072			958			3,076			2,835
Interest income			3,729			5,653			11,012			15,611
Interest expense			(3,002)			(3,224)			(9,003)			(10,471)
Loss from debt extinguishment			—			—			—			(27,950)
Other non-operating items			(1,447)			7,076			(3,037)			(1,103)
Net loss		$	(69,418)		$	(36,493)		$	(201,285)		$	(145,118)

(a)

excluding stock-based compensation, depreciation, and facilities expenses

(b)

excluding stock-based compensation and depreciation